Y
Yaming Li
Researcher at Shandong University
Publications - 67
Citations - 1984
Yaming Li is an academic researcher from Shandong University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 19, co-authored 38 publications receiving 1076 citations.
Papers
More filters
Journal ArticleDOI
LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303/PTBP3 axis
Yiran Liang,Xiaojin Song,Yaming Li,Bing Chen,Wenjing Zhao,Lijuan Wang,Hanwen Zhang,Ying Liu,Dianwen Han,Ning Zhang,Tingting Ma,Yajie Wang,Fangzhou Ye,Dan Luo,Xiaoyan Li,Qifeng Yang +15 more
TL;DR: Results reveal a novel HIF-1α/lnc RNA BCRT1/miR-1303/PTBP3 pathway for breast cancer progression and suggest that lncRNA B CRT1 might be a potential biomarker and therapeutic target for breast cancers.
Journal ArticleDOI
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer
Yuting Sang,Bing Chen,Xiaojin Song,Yaming Li,Yiran Liang,Dianwen Han,Ning Zhang,Hanwen Zhang,Ying Liu,Tong Chen,Chen Li,Lijuan Wang,Wenjing Zhao,Qifeng Yang +13 more
TL;DR: Hsa_circ_0025202 served an anti-oncogenic role in HR-positive breast cancer, and it could be exploited as a novel marker for tamoxifen-resistant breast cancer.
Journal ArticleDOI
LncRNA-CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215.
Xiaoli Kong,Yi Duan,Yuting Sang,Yaming Li,Hanwen Zhang,Yiran Liang,Ying Liu,Ning Zhang,Qifeng Yang +8 more
TL;DR: It is proved that lncRNA–CDC6 could function as ceRNA and promote the proliferation and metastasis of breast cancer cells, which provided a novel prognostic marker for breast cancers in clinic.
Journal ArticleDOI
MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1
TL;DR: It is proved that miR-770 could suppress the doxorubicin-resistance and metastasis of TNBC cells, which broaden the insights into the underlying mechanisms in chemo-res resistance and metastases, and provided a new prognostic marker for T NBC cells.
Journal ArticleDOI
circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer.
Yiran Liang,Xiaojin Song,Yaming Li,Peng Su,Dianwen Han,Tingting Ma,Renbo Guo,Bing Chen,Wenjing Zhao,Yuting Sang,Ning Zhang,Xiaoyan Li,Hanwen Zhang,Ying Liu,Yi Duan,Lijuan Wang,Qifeng Yang +16 more
TL;DR: The data indicate that circKDM4C might have considerable potential as a prognostic biomarker in breast cancer, and support the notion that therapeutic targeting of circK DM4C/miR-548p/PBLD axis may be a promising treatment approach for breast cancer patients.